Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early prolonged methylprednisolone for acute lung injury and ARDS
2007-005901-23Phase 3Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) comparing Methylprednisolone with Placebo (2 arms). Primary endpoint: All-cause 28 day mortality. Started Dec 2007; status: terminated.
02
Drugs
methylprednisolone
03
Conditions
acute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2007-005901-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005901-23.